Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. reported option exercises and related share movements involving Fairmount-affiliated entities. On 2026-08-07, options to acquire 31,838 and 10,370 shares of common stock were exercised at strike prices of $17.00 and $43.85 per share, respectively. The resulting common shares are held indirectly through Fairmount Healthcare Fund II L.P., with 51,166 shares reported as indirectly held for each of Tomas Kiselak and Peter Harwin, who, along with Fairmount, disclaim beneficial ownership except to the extent of their pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 42,208 shares
Net Buy
6 txns
Insider
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Kiselak Tomas, Harwin Peter Evan
Role
Director | Director | Director | Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2, F3 | 31,838 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F4, F3 | 10,370 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 31,838 | $17.00 | $541K |
| Exercise | Common Stock F1 | 10,370 | $43.85 | $455K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 340,855 shares (Indirect, By Fairmount Healthcare Fund II LP);
Common Stock — 51,166 shares (Indirect, By Tomas Kiselak);
Common Stock — 51,166 shares (Indirect, By Peter Harwin)
Footnotes (4)
- F1. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F2. This option represented the vested portion of the total right to purchase 47,758 shares of the Issuer's common stock, which vested in three approximately equal annual installments beginning on the first anniversary of the 7/13/2023 grant date.
- F3. Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock.
- F4. This option represented the right to purchase 10,370 shares of the Issuer's common stock, which vested on the one-year anniversary of the 6/5/2024 grant date.
Key Figures
Options Exercised at $17.00: 31,838 shares
Options Exercised at $43.85: 10,370 shares
Total Options Exercised: 42,208 shares
+3 more
6 metrics
Options Exercised at $17.00
31,838 shares
Stock options exercised on 2026-08-07 at $17.00 per share
Options Exercised at $43.85
10,370 shares
Stock options exercised on 2026-08-07 at $43.85 per share
Total Options Exercised
42,208 shares
Aggregate derivative exercises (code M) reported for 2026-08-07
Indirect Holdings per Individual
51,166 shares
Common stock indirectly held for each of Tomas Kiselak and Peter Harwin
Option Expiration 1
07/13/2033
Expiration date of option originally for 47,758 shares, 31,838 exercised
Option Expiration 2
06/05/2034
Expiration date of option for 10,370 shares, fully vested and exercised
Key Terms
Stock Option (Right to Buy), beneficial ownership, pecuniary interest, director by deputization
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
beneficial ownership financial
"disclaim beneficial ownership of any of the reported securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of their pecuniary interest therein"
director by deputization regulatory
"may each be deemed a director by deputization of the Issuer"
FAQ
How many Apogee (APGE) options were exercised and at what prices?
Two option blocks were exercised: 31,838 shares at a strike price of $17.00 and 10,370 shares at $43.85 per share. These exercises converted stock options into common shares held indirectly via Fairmount Healthcare Fund II L.P.
What are the reported indirect holdings after these APGE transactions?
Following the reported transactions, 51,166 Apogee common shares are shown as indirectly held for Tomas Kiselak and 51,166 shares for Peter Harwin. The footnotes state that Fairmount, Harwin, and Kiselak disclaim beneficial ownership except for any pecuniary interest.
Were the Apogee (APGE) option exercises under a Rule 10b5-1 plan?
The filing indicates the Rule 10b5-1 checkbox was not marked, and no footnote describes a trading plan. The transactions are therefore reported without being identified as executed under a pre-arranged Rule 10b5-1 trading plan.
Who is attributed with these APGE transactions in the Form 4?
The transactions involve Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak. Footnotes explain that options were held for Fairmount-managed funds and that the individuals and Fairmount disclaim beneficial ownership beyond their pecuniary interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
